SIMVASTATIN; SITAGLIPTIN PHOSPHATE
| Brand name | JUVISYNC |
|---|---|
| Active ingredient | SIMVASTATIN; SITAGLIPTIN PHOSPHATE |
| Strength | 40MG;EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** |
| Dosage form | TABLET |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | September 2012 |
| Marketing status | DISCN |
| Patent | Expires | Type |
|---|---|---|
| 7326708*PED | October 2026 | — |
| 7326708 | April 2026 | substance, product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.